Skip to main content
Heidelberg Pharma AG logo

Heidelberg Pharma AG — Investor Relations & Filings

Ticker · HPHA ISIN · DE000A11QVV0 LEI · 391200E09XYBYITR1W32 F Manufacturing
Open in API
Filings indexed 806 across all filing types
Latest filing 2026-05-15 AGM Information
Country DE Germany
Listing F HPHA

About Heidelberg Pharma AG

https://heidelberg-pharma.com/en/

Heidelberg Pharma AG is a clinical-stage biopharmaceutical company specializing in the development of targeted cancer therapies. The company's core focus is its proprietary Antibody-Drug Conjugate (ADC) technology platform, which utilizes the toxin Amanitin. This platform, known as Antibody Targeted Amanitin Conjugates (ATACs®), is designed to deliver the highly potent Amanitin payload directly to tumor cells. Heidelberg Pharma is the first company to advance Amanitin into clinical development for cancer treatment. Its lead candidate, HDP-101, is in clinical trials for patients with multiple myeloma. The company leverages its ADC expertise to create novel medicines for oncology.

Recent filings

Filing Released Lang Actions
Heidelberg Pharma AG: Bekanntmachung der Einberufung zur Hauptversammlung am 23.06.2026 in Ladenburg mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information Classification · 85% confidence The document is the formal announcement (Einberufung) of the Annual General Meeting (Hauptversammlung) of Heidelberg Pharma AG scheduled for June 23, 2026. It contains the invitation, agenda items, participation instructions, and voting procedures for shareholders. This fits the definition of AGM Information (AGM-R).
2026-05-15 German
Q1 statement / Q1 financial report 2025/2026
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Statement on the First Three Months of Financial Year 2026' and covers detailed financial and operational information for Heidelberg Pharma AG for the period 1 December 2025 to 28 February 2026 (Q1 2026). It includes comprehensive financial figures such as sales revenue, operating expenses, net loss, balance sheet data, cash flow, and employee numbers. It also discusses clinical trial progress, milestone payments, management changes, and financial outlook for the year 2026. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is a full interim financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2026-04-30 English
Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2026
Interim / Quarterly Report Classification · 98% confidence The document is titled “Interim Statement on the First Three Months of Financial Year 2026,” is issued by the company as a standalone report, and contains detailed quarter‐end financial figures (income statement items, balance sheet figures, cash flow, outlook, narrative management commentary). It is clearly a comprehensive interim/quarterly report rather than a brief announcement or an attached Excel supplement. Therefore, it fits the definition of an Interim/Quarterly Report. Q1 2026
2026-04-29 English
Heidelberg Pharma Announces Change in Executive Board
Board/Management Information Classification · 85% confidence The document is a press release corporate news announcement detailing a change in the company’s executive board (CFO departure and new appointment). This falls squarely under Board/Management Information (personnel changes at senior management level). It is not an earnings release or an annual/interim report, nor a publication notice. Therefore, the correct classification is MANG.
2026-04-17 English
Heidelberg Pharma AG: Heidelberg Pharma Determines Recommended Dose for Phase II Trial with ADC Candidate HDP-101
Regulatory Filings Classification · 92% confidence The document is an ad-hoc press release disclosing inside information under EU MAR, announcing clinical trial progress (selected Phase II dose) rather than financial results, management changes, vote outcomes, or offering shareholder materials. It is a general regulatory/corporate announcement that does not fit earnings releases, capital changes, or other specific categories. Therefore it falls under the fallback category for miscellaneous regulatory announcements (RNS).
2026-04-09 English
Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026
Regulatory Filings Classification · 60% confidence The document is a corporate press release about Heidelberg Pharma’s planned scientific presentation at an academic conference (AACR Annual Meeting 2026). It does not contain earnings figures, votes, legal proceedings, financing details, or report attachments. It is not an investor presentation deck or an actual financial report. Therefore it falls into the miscellaneous regulatory announcement category: Regulatory Filings (RNS).
2026-04-04 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.